Volume 12, Issue 4 (12-2024)                   JoMMID 2024, 12(4): 270-277 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ameena B, Sriram D, Kundapur A. Evaluating Rubella Immunity in Women of Reproductive Age in Mysuru: A Cross-Sectional Serosurvey. JoMMID 2024; 12 (4) :270-277
URL: http://jommid.pasteur.ac.ir/article-1-604-en.html
Evaluating Rubella Immunity in Women of Reproductive Age in Mysuru: A Cross-Sectional Serosurvey
Beebi Ameena * , Deepa Sriram , Anuradha Kundapur
Department of Microbiology, Mysore Medical College and Research Institute, India
Abstract:   (119 Views)
Introduction: This study aimed to determine the seroprevalence of rubella IgG antibodies among women of reproductive age in Mysuru, India. Estimating the rubella seroprevalence in this populationis crucial for informing public health interventions aimed at preventing congenital rubella syndrome (CRS), a severe birth defect caused by rubella infection during pregnancy. Methods: A cross-sectional serosurvey was conducted among women of reproductive age (18–38 years) in Mysuru city from January 15, 2019, to December 31, 2019. A total of 311 participants were recruited using a convenience sampling technique. Rubella IgG antibody levels were measured using ELISA with the CALBIOTECH Rubella IgG ELISA kit. Results: The mean age of the 311 women of reproductive age included in the study was 25.8 ± 5.2 years. Age was not significantly associated with rubella IgG antibody status (P=0.123). Overall, 95.5% (n = 297) of participants were seropositive for rubella IgG antibodies, indicating immunity against rubella. The lowest seroprevalence (92.1%, n = 51) was observed in the 21–25 years age group. Although not statistically significant (P=0.872), a slightly higher proportion of urban residents (95.68%, n = 267) were seropositive compared to rural residents. Furthermore, participants with a history of normal pregnancy (98.59%, n = 166) and those who reported being vaccinated (100%) had a significantly higher seroprevalence of rubella IgG antibodies. Conclusion: This study found a high seroprevalence of rubella IgG antibodies (95.5%) among women of reproductive age in Mysuru, indicating a potentially low risk of rubella infection and a high level of population immunity. This high seroprevalence is likely attributable to the successful implementation of the national Measles-Rubella vaccination campaign in India, as evidenced by the high seroprevalence observed self-reported vaccinated participants. Further research is warranted to investigate the duration of rubella immunity conferred by vaccination and to assess the need for booster doses in this population.
 
Keywords: Rubella, Seroepidemiologic Study, Immunoglobulin G, Pregnancy, Vaccination
Full-Text [PDF 337 kb]   (40 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2023/09/29 | Accepted: 2024/12/21 | Published: 2025/03/1
attachement [PDF 297 KB]  (7 Download)
References
1. Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol. 1990; 64 (2): 700-5. [DOI:10.1128/jvi.64.2.700-705.1990] [PMID] [PMCID]
2. World Health Organisation. Rubella [Internet]. Geneva: World Health Organization. 2014 [cited 2023 May 16]; Available from: https://www.who.int/news-room/fact-sheets/detail/rubella
3. Ministry of Health and Family Welfare, Government of India. National strategic plan for achieving and sustaining measles and rubella elimination in India [Internet]. 2020. [cited 2023 June 1]; Available from: https://nhm.hp.gov.in/storage/app/media/uploaded-files/MR%20Strategic%20Plan%20India.pdf
4. Murugan R, VanderEnde K, Dhawan V, Haldar P, Chatterjee S, Sharma D, et al. Progress Toward Measles and Rubella Elimination - India, 2005-2021. Morb Mortal Wkly Rep. 2022; 71 (50): 1569-75. [DOI:10.15585/mmwr.mm7150a1] [PMID] [PMCID]
5. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982; 2 (8302): 781-4. [DOI:10.1016/S0140-6736(82)92677-0] [PMID]
6. Ramana BV, Reddy BK, Murty DS, Vasudevanaidu KH. Seroprevalence of Rubella in Women with Bad Obstetric History. J Family Med Prim Care. 2013; 2 (1): 44-6. [DOI:10.4103/2249-4863.109943] [PMID] [PMCID]
7. Best JM, O'Shea S, Tipples G, Davies N, Al-Khusaiby SM, Krause A, et al. Interpretation of rubella serology in pregnancy-pitfalls and problems. BMJ. 2002; 325 (7356): 147-8. [DOI:10.1136/bmj.325.7356.147] [PMID] [PMCID]
8. Almeida JD, Griffith AH. Viral infections and rheumatic factor. Lancet. 1980; 2 (8208-8209): 1361-2. [DOI:10.1016/S0140-6736(80)92419-8] [PMID]
9. Sharma HJ, Padbidri VS, Kapre SV, Jadhav SS, Dhere RM, Parekh SS, et al. Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India. J Infect Dev Ctries. 2011; 5 (12): 874-81. [DOI:10.3855/jidc.1847] [PMID]
10. Bavdekar SB, Karande S. Elimination of measles from India: Challenges ahead and the way forward. J Postgrad Med. 2017; 63 (2): 75-78. [DOI:10.4103/jpgm.JPGM_166_17] [PMID] [PMCID]
11. Kori BK, Singh KN, Sharma RK, Sharma BS, Badkur P, Barde PV. Susceptibility of Rubella Among Pregnant Women Attending the Antenatal Clinic in a Tertiary Care Hospital, Jabalpur, Central India. Viral Immunol. 2017; 30 (2): 136-9. [DOI:10.1089/vim.2016.0106] [PMID]
12. Daniel WW. Determination of sample size for estimating proportions. Biostatistics A foundation for analysis in the health sciences. Sci Res. 1999; 8: 189-90.
13. Rubella IgG ELISA Catalog No: RB025G (96 Tests) [Print]. California: CALBIOTECH 2017 [cited 2024 Jan 7]; Available from: https://cdn.shopify.com/s/files/1/0538/1921/1960/files/RB025G-R7_RC.pdf?
14. CoGuide. Research Enablement and Productivity Platform (REAP), version 2.0. Released 2022; India: BDSS Corp.
15. Karunakaran L, Madhavan A, Devadasan S, Asokan A, Joseph A. Seroprevalence of Rubella IgG in Women of Reproductive Age Group in a Tertiary Care Teaching Hospital. J Pure Appl Microbiol. 2022; 16 (4): 2639-2646. [DOI:10.22207/JPAM.16.4.31]
16. Corcoran C, Hardie DR. Seroprevalence of rubella antibodies among antenatal patients in the Western Cape. S Afr Med J. 2005; 95 (9): 688-90.
17. Taku NA, Ndze VN, Abernathy E, Hao L, Waku-Kouomou D, Icenogle JP, et al. Seroprevalence of rubella virus antibodies among pregnant women in the Center and South-West regions of Cameroon. PLoS One. 2019; 14 (11): e0225594. [DOI:10.1371/journal.pone.0225594] [PMID] [PMCID]
18. Bukbuk DN, el Nafaty AU, Obed JY. Prevalence of rubella-specific IgG antibody in non-immunized pregnant women in Maiduguri, north eastern Nigeria. Cent Eur J Public Health. 2002; 10 (1-2): 21-3.
19. Crooke SN, Haralambieva IH, Grill DE, Ovsyannikova IG, Kennedy RB, Poland GA. Seroprevalence and Durability of Rubella Virus Antibodies in a Highly Immunized Population. Vaccine. 2019; 37 (29): 3876-82. [DOI:10.1016/j.vaccine.2019.05.049] [PMID] [PMCID]
20. Zanella B, Boccalini S, Bonito B, Del Riccio M, Manzi F, Tiscione E, et al. Rubella Seroprevalence Boost in the Pediatric and Adolescent Population of Florence (Italy) as a Preventive Strategy for Congenital Rubella Syndrome (CRS). Vaccines (Basel). 2020; 8 (4): 599. [DOI:10.3390/vaccines8040599] [PMID] [PMCID]
21. Chattopadhyay S, Biswas T, Chakraborty B, Mukherjee T, Ghosh P, Mondal R. Sero-prevalence of Rubella Antibodies in Pregnant Women with Bad Obstetric History Attending A Rural Tertiary Care Hospital in West Bengal, India. IJMDS. 2019; 1749-53. [DOI:10.18311/ijmds/2019/23313]
22. Pandolfi E, Gesualdo F, Rizzo C, Bella A, Agricola E, Mastroiacovo P, et al. Global seroprevalence of rubella among pregnant and childbearing age women: a meta-analysis. Eur J Public Health. 2017; 27 (3): 530-7. [DOI:10.1093/eurpub/ckw259] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.